What is HC Wainwright’s Estimate for TNYA Q1 Earnings?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for Tenaya Therapeutics in a research report issued on Tuesday, March 11th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.14) per share for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Tenaya Therapeutics’ Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.59) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.51) EPS and FY2028 earnings at ($0.58) EPS.

A number of other research firms also recently commented on TNYA. Morgan Stanley dropped their price objective on Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday. Chardan Capital dropped their price target on shares of Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Canaccord Genuity Group reduced their price objective on shares of Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $6.25.

Tenaya Therapeutics Price Performance

Shares of TNYA stock opened at $0.67 on Thursday. The firm has a market cap of $53.09 million, a P/E ratio of -0.47 and a beta of 2.83. Tenaya Therapeutics has a fifty-two week low of $0.39 and a fifty-two week high of $5.39. The stock’s 50-day moving average is $1.08 and its two-hundred day moving average is $1.84.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04.

Hedge Funds Weigh In On Tenaya Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TNYA. State Street Corp increased its holdings in shares of Tenaya Therapeutics by 0.9% during the 3rd quarter. State Street Corp now owns 1,058,898 shares of the company’s stock worth $2,044,000 after purchasing an additional 9,506 shares during the period. Synovus Financial Corp acquired a new stake in Tenaya Therapeutics during the third quarter worth about $28,000. SG Americas Securities LLC increased its stake in Tenaya Therapeutics by 61.9% during the fourth quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock valued at $59,000 after acquiring an additional 15,777 shares during the period. XTX Topco Ltd raised its holdings in Tenaya Therapeutics by 51.2% in the 3rd quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after acquiring an additional 16,687 shares in the last quarter. Finally, Atticus Wealth Management LLC raised its stake in shares of Tenaya Therapeutics by 56.3% in the fourth quarter. Atticus Wealth Management LLC now owns 47,762 shares of the company’s stock valued at $68,000 after purchasing an additional 17,199 shares in the last quarter. Institutional investors own 90.54% of the company’s stock.

Insider Buying and Selling at Tenaya Therapeutics

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III purchased 35,714,284 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was bought at an average cost of $0.70 per share, for a total transaction of $24,999,998.80. Following the completion of the acquisition, the insider now directly owns 49,313,559 shares in the company, valued at $34,519,491.30. This represents a 262.62 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 19,621 shares of company stock worth $10,595 over the last ninety days. Company insiders own 32.76% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.